- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06111768
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study (SGLT2i in CRS)
Study Overview
Detailed Description
Acute heart failure is associated with a significant risk of acute kidney injury which is present in up to a third of patients at the time of hospitalization. As adequate kidney function is necessary for self-decongestion, kidney injury makes the treatment of acute heart failure particularly challenging. SGLT2i are drugs consistently shown to reduce hospitalizations in heart failure as well as progression of kidney disease but are frequently discontinued during acute kidney injury. Although they have been included in the armamentarium of heart failure care as guideline directed medical therapy, a concern about the efficacy and safety in patients with kidney dysfunction remains a limitation to their widespread uptake particularly during heart failure exacerbation.
This study aims to enroll adults hospitalized with acute congestive cardiorenal syndrome and develop acute kidney injury in a randomized clinical trial of SGLT2i versus usual care to compare markers of decongestion and biomarkers of kidney injury and health to inform a larger randomized clinical trial. The overall aim is to assess if SGLT2i improve diuretic efficiency in patients with heart failure associated kidney injury. The long-term goal of this study is to promote increased use of SGLT2i by demonstrating their safety and possible benefit in patients who develop heart failure associated kidney injury to avoid interruptions in this setting.
The primary objective of this is study is to test the feasibility and acceptability of randomizing adults hospitalized with acute heart failure complicated by acute kidney injury to SGLT2i or usual care.
The secondary objectives of this study are:
- To compare changes in biomarkers of kidney injury, repair and tubular function in order to test whether the SGLT2 inhibitor (dapagliflozin) improves response to standard treatment
- To compare markers of decongestion (weight, urine volume, symptom score, diuretic de-escalation) to test whether the addition of SGLT2i to standard of care improves heart failure symptoms faster.
- To compare possible adverse events such as: sodium or potassium derangements, metabolic acidosis, urinary tract infections (UTI) or genital mycotic infections in those exposed to the SGLT2i dapagliflozin vs usual care.
- To compare hospital length of stay, mortality, progression to a higher stage of AKI, and persistent AKI at discharge
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Abinet Aklilu
- Phone Number: (203) 931-5064
- Email: abinet.aklilu@yale.edu
Study Contact Backup
- Name: Perry Wilson
- Phone Number: (203) 764-8373
- Email: francis.p.wilson@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale New Haven Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged ≥ 18 and ≤ 85 years-old
- Diagnosed with heart failure of either preserved or reduced left ventricular function
- NT-proBNP > 300 pg/mL
- Ability to take an oral medication
- Willing to adhere to the SGLT2i + usual care regimen
Exclusion Criteria:
- Current use of SGLT2 inhibitor or use in the past 72 hours
- Pregnancy or lactation (a pregnancy test will be performed prior to enrollment in women of child-bearing age)
- Known allergic reactions to components of an SGLT2 inhibitor
- Treatment with another investigational drug for heart failure different from or in addition to usual care within the 72 hours preceding AKI
Any individual who meets any of the following criteria will be excluded from participation in this study:
- Documented history of ileal conduit (neobladder)
- No means of collecting urine such as patients with documented incontinence without indwelling or external urinary catheter
- Advanced kidney disease at baseline defined as baseline eGFR < 25 ml/min/1.73m2
- Unexplained hypoglycemia in the past 30 days from enrollment
- History of Fournier's gangrene (pelvic necrotizing fasciitis)
- History of recurrent urinary tract infection (UTI): defined as documented UTI at least 2x in the past 6 months or 3 x in the past 12 months
- End-stage kidney disease with dialysis requirement
- Oliguria: defined as less than 30 ml urine output per hour for more than two consecutive hours or less than 500 ml over the preceding 24 hours
- Severe acute kidney injury with indications for dialysis
- Current dialysis receipt for acute kidney injury
- Comfort measures only
- Solid organ transplant on immunosuppression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SGLT2i administration
A 10 mg oral dose of dapagliflozin will be administered daily for three days.
|
Receipt of 10mg oral dose of dapagliflozin once daily for three days
|
No Intervention: Usual Care
Subjects continue with usual care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of eligible versus consented patients
Time Frame: From study initiation to study close (about 2 years)
|
Number of patients deemed eligible after assessment of inclusion and exclusion criteria and number of patients who consent, which serves as a measure of feasibility of enrolling patients with acute cardiorenal syndrome in a randomized clinical trial of SGLT2i.
|
From study initiation to study close (about 2 years)
|
Percentage of enrolled patients with completed sample collections
Time Frame: From study initiation to study close (about 2 years)
|
Percentage of enrolled patients who have provided at least two days of urine samples and percentage of enrolled patients who have provided at least two days of blood samples, which serves as a measure of feasibility of enrolling and retaining patients with acute cardiorenal syndrome in a randomized clinical trial of SGLT2i.
|
From study initiation to study close (about 2 years)
|
Enrollment rate
Time Frame: From study initiation to study close (about 2 years)
|
Total enrollment into the study over study duration, to serve as a measure of feasibility.
|
From study initiation to study close (about 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Slope of creatinine
Time Frame: 5 days following randomization
|
Comparison between study arms of the slope of the serum biomarker creatinine over five days, as a measure of kidney function
|
5 days following randomization
|
Slope of cystatin-C
Time Frame: 5 days following randomization
|
Comparison between study arms of the slope of the serum biomarker cystatin-C over five days, as a measure of kidney function
|
5 days following randomization
|
Slope of NT-proBNP
Time Frame: 5 days following randomization
|
Comparison between study arms of the slope of the serum biomarker NT-proBNP over five days, as a measure of decongestion.
|
5 days following randomization
|
Slope of kidney tubular injury and repair biomarkers
Time Frame: 5 days following randomization
|
Comparison between study arms of the slopes of the following urinary biomarkers of renal tubular kidney injury, inflammation and repair over five days: molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), monocyte chemoattractant protein-1 (MCP-1), uromodulin (UMOD), chitinase-3-like protein (YKL-40).
|
5 days following randomization
|
Slope of urine volume
Time Frame: 72 hours from randomization
|
Comparison between study arms of 24 hour urine volume collection as a measure of decongestion
|
72 hours from randomization
|
Weight
Time Frame: 72 hours from randomization
|
Weight of subjects at 72 hours post-randomization as a measure of decongestion.
|
72 hours from randomization
|
Breathlessness score
Time Frame: 72 hours from randomization
|
Based on the 3 item symptom scale questionnaire given to subjects.
Breathlessness scores range from 1-5, with higher scores indicating higher breathlessness.
This score serves as a measure of decongestion.
|
72 hours from randomization
|
Loop diuretic dose de-escalation
Time Frame: From randomization up to 72 hours from randomization
|
Time from randomization to de-escalation of loop diuretic, serving as a measure of decongestion.
|
From randomization up to 72 hours from randomization
|
Mortality
Time Frame: Assessed from randomization to time of death up to 14 days post-randomization or discharge
|
Time to in-hospital death
|
Assessed from randomization to time of death up to 14 days post-randomization or discharge
|
Dialysis
Time Frame: Assessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 14 days post-randomization or discharge
|
Time to in-hospital dialysis
|
Assessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 14 days post-randomization or discharge
|
Rate of rehospitalization with heart failure
Time Frame: 90 days post-index discharge
|
Number of patients rehospitalized for heat failure after index hospitalization, wtihin 90 days of discharge
|
90 days post-index discharge
|
Time-to-prescription of an SGLT2i
Time Frame: 90 days post-randomization
|
Time to prescription of any SGLT2 by patient's primary provider, up to 90 days post-randomization
|
90 days post-randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Abinet Aklilu, Yale University
- Principal Investigator: Perry Wilson, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Kidney Diseases
- Urologic Diseases
- Disease
- Renal Insufficiency
- Heart Failure
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Syndrome
- Cardio-Renal Syndrome
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Dapagliflozin
Other Study ID Numbers
- 2000036118
- 000 (Other Identifier: CTGTY)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiorenal Syndrome
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiorenal Syndrome (CRS)United States
-
Instituto Nacional de Cardiologia Ignacio ChavezEchoNous Inc.RecruitingCardiorenal Syndrome Type 1Mexico
-
Chulalongkorn UniversityNot yet recruitingEmpagliflozin in Cardiorenal Syndrome Type 1Thailand
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Enrolling by invitationHeart Failure | Cardiorenal Disease | Renal DisfunctionUnited States
-
Hospital Civil de GuadalajaraCompleted
-
Horng ChenFlowMedica, Inc.TerminatedCardiorenal SyndromeUnited States
-
Maimonides Medical CenterWithdrawn
-
Ankara UniversityCompletedCardiorenal SyndromeTurkey
-
Göteborg UniversitySahlgrenska University Hospital, SwedenCompletedCardiorenal SyndromeSweden
-
Virginia Commonwealth UniversityTerminatedCongestive Heart Failure | Cardiorenal SyndromeUnited States
Clinical Trials on Dapagliflozin
-
AstraZenecaRecruitingLiver CirrhosisDenmark, Spain, Germany, United States, France, Australia, China, Belgium, Netherlands, Switzerland, Austria, United Kingdom, Taiwan, Canada, Czechia
-
AstraZenecaRecruitingHeart Failure and Impaired Kidney FunctionSpain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Brazil, Finland, Greece, Israel, Mexico, United Kingdom, Turkey, Colombia, Slov... and more
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands